Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination. Continue your routine care with us by scheduling an in-person appointment or Video Visit.

Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma.

TitleSerum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma.
Publication TypeJournal Article
Year of Publication2015
AuthorsVij R, Wang M, Jagannath S, Niesvizky R, Jakubowiak AJ, Kavalerchik E, Huang M, Siegel DS
JournalLeuk Lymphoma
Volume56
Issue10
Pagination2959-61
Date Published2015
ISSN1029-2403
KeywordsAntineoplastic Agents, Biomarkers, Tumor, Drug Resistance, Neoplasm, Humans, Immunoglobulin Light Chains, Multiple Myeloma, Oligopeptides, Prognosis, Proteasome Inhibitors, Recurrence, Retrospective Studies, Treatment Outcome
DOI10.3109/10428194.2015.1020801
Alternate JournalLeuk. Lymphoma
PubMed ID25699653